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Background: Comparison of antimicrobial de-escalation rates between healthcare settings is problematic. To
objectively and electronically measure de-escalation a method based upon the spectrum of antimicrobial regimens
administered (i.e., spectrum score) was developed.
Methods: A Delphi process was used to develop applicable concepts. Spectrum scores were created for 27
antimicrobials based upon susceptibility for 19 organisms. National VA susceptibility data was used to estimate
microbial spectrum. Susceptibility estimates were converted to ordinal scores, and values for organisms with multi-
drug resistance potential were weighted more heavily. Organism scores were summed to create antibiotic-specific
spectrum scores and extended mathematically to score multi-antimicrobial regimens. Vignettes were created from
antimicrobial regimens administered to 300 patients hospitalized with pneumonia. Daily spectrum scores were
calculated for each case. Hospitalization day 4 scores were subtracted from day 2 scores (i.e., spectrum score Δ). A
positive spectrum score Δ defined de-escalation. Experts ranked each pneumonia case on a 7-point Likert scale
(Likert >4 indicated de-escalation). Spectrum score Δs were compared to expert review. Findings were used to
identify score deficiencies. Next, 40 pairs of cases were modified to include antimicrobial administration routes. Each
pair contained almost similar regimens; however, one contained oral (PO) the other only intravenous (IV) antimicrobials
on day 4 of therapy. Experts reviewed cases as described. Spectrum score Δ credits to account for PO conversion were
derived from the mean paired differences in Likert Score. De-escalation status was evaluated in 100 vignettes containing
antimicrobial route by different experts and compared to the modified method.
Results: Initial sensitivity and specificity of the spectrum score Δ to detect expert classified de-escalation events was
86.3 and 96.0%, respectively. In paired cases, the mean (± SD) Likert score was 5.0 (1.5) and 4.6 (1.5) for PO and IV
(P = 0.002), respectively. To improve de-escalation event detection, two credits were added to spectrum score Δs based
upon the percentage of antimicrobials administered PO on day 4. The final method, exhibited sensitivity and specificity
to detect expert classified de-escalation events of 96.2 and 93.6%, respectively.
Conclusions: The final spectrum score method exhibited excellent agreement with expert judgments of de-escalation
events in pneumonia.
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In response to increasing antimicrobial resistance, profes-
sional and governmental organizations recommend that
hospital-based programs practice antimicrobial steward-
ship [1-3]. Antimicrobial stewardship refers to coordi-
nated interventions to optimize the selection, dose, and
duration of antimicrobial therapy, while limiting adverse
events, cost, and antimicrobial resistance. Antimicrobial
de-escalation is a fundamental operation of antimicrobial
stewardship [1-5].
Antimicrobial de-escalation refers to a reduction in
the antimicrobial “spectrum” of therapy, through discon-
tinuation of antimicrobials providing activity against
non-pathogenic flora or changing antimicrobials to limit
coverage to targeted pathogens once a patient is clinic-
ally stable [1-5]. Stopping antimicrobials with overlap-
ping spectrum or, discontinuing antimicrobials if an
infection is unlikely may also be considered antimicro-
bial de-escalation [5,6]. In studies, de-escalation has
been defined and measured subjectively based upon vari-
able qualitative assessments [5]. Further, manual chart
review is required to determine if antimicrobial de-
escalation has occurred. Comparison of antimicrobial
de-escalation practice is limited due to a lack of object-
ive measurement criteria and automated measurement
methods.
We developed a method to measure antimicrobial de-
escalation, which was based upon the spectrum of anti-
microbial regimens administered that can be applied to
electronic medical records data (i.e., spectrum score
method). The methodological framework was based
upon the opinions of antimicrobial stewards for con-
cepts relevant to antimicrobial de-escalation, which were
obtained through a Delphi process. The method was de-
veloped to estimate facility-level de-escalation rates with
data from the U.S. Veterans Healthcare Administration
(VA) Computerized Patient Record System. A description
of the Delphi panel findings and a preliminary overview of
the spectrum score method have been reported [7].
The purpose of this manuscript is to provide a detailed
description of the spectrum score method, including: the
approach to assignment of spectrum scores to antimi-
crobials, application of the scores to electronic medical
records data to generate spectrum scores for antimicro-
bial regimens; refinement and validation of the method
to measure antimicrobial de-escalation in patients with
Healthcare Associated Pneumonia (HCAP). HCAP was
selected for evaluation because broad-spectrum empirical
antimicrobial therapy and de-escalation are indicated [8].
Methods
The spectrum score method involves assignment of a
numerical score to each calendar day of antimicrobial
therapy administered during hospitalization based onthe microbial spectrum of the regimen. Antimicrobial
de-escalation is quantified by subtracting the regimen’s
spectrum score for day 4 of hospitalization from a base-
line score obtained for antimicrobials administered on
day 2 of hospitalization (i.e., spectrum score Δ). A posi-
tive spectrum score Δ suggests that microbial spectrum
coverage has been narrowed and that de-escalation has
occurred.
Assignment of spectrum score to antimicrobials
The approach to assigning a numerical spectrum score
to antimicrobial regimens has recently been summarized
[7]. First, national VA Corporate Data Warehouse (CDW)
susceptibility data for organisms and antimicrobials tested
during years 2008–2012 were used to estimate antimicro-
bial susceptibility if available. The VA CDW includes cul-
ture and susceptibility results for 7 million veterans who
receive care in 152 medical centers. Percent susceptibility
was calculated for individual antimicrobial-organism pairs
utilizing one isolate per patient per year. Next, remaining
organism-antimicrobial pairs were categorized as posses-
sing no intrinsic activity (NA), no VA susceptibility data
available (ND), or further confirmation of susceptibility
estimates required. NA classifications were based upon
current FDA approved prescribing information, Clinical
Laboratory Standards Institute (CLSI) standards for sus-
ceptibility testing, and tertiary references [9-42]. Current
CLSI reporting recommendations were applied preferen-
tially. For example, the CLSI-based susceptibility of
Staphylococcus aureus to oxacillin was used to populate
the susceptibility values for other β-lactams (except cef-
taroline) with activity against Staphylococcus aureus.
Organism-antimicrobial pairs without approved suscepti-
bility methods, but suppressed results, were handled in-
dividually; where possible findings were cross-referenced
with susceptibility results identified through literature
sources.
Assignment of scores to organism-antimicrobial pairs
without susceptibility data was directed by several data
sources, and in some cases more than one data source
was used. Primary literature was evaluated for suscepti-
bility studies. Preference was given to results from stud-
ies which included U.S. based isolates, referenced CLSI
methods, and recent studies. In some cases, CLSI docu-
ments provided estimates of susceptibility, in other
cases, if recent product labeling indicated that the anti-
microbial possessed in vitro activity against > 90% of the
isolates tested in clinical trials, a value of 90% was
assigned. Infrequently, suitable references could not be
identified, and investigator opinion was utilized to assign
susceptibility. To enhance generalizability and apply
susceptibility data to be more representative of different
practice environments, percentage susceptibilities were
converted into quintiles ranging from 0 points for
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80-100%. Assignment of ordinal scores to organism-
antimicrobial pairs without VA susceptibility data was per-
formed independently by two investigators (KM, BH) with
adjudication of discrepancies by a 3rd investigator (MJ).
Spectrum score adjustment for intrinsically resistant
organisms
Delphi panelists indicated that antimicrobials covering
organisms with high potential for developing resistance
should receive extra weight in the spectrum score [7].
Consistent with panelist preferences, ordinal susceptibil-
ity values for organism-antimicrobial pairs involving
Staphylococcus aureus, Enterococcus faecium, Escheri-
chia coli, Klebsiella spp., and Acinetobacter spp. were
multiplied by a factor of 1.25, and Pseudomonas aerugi-
nosa was multiplied by a factor of 1.75. Domains for
each organism’s weighted or un-weighted scores were
added to create a composite spectrum score for each
antimicrobial on a 0–60 spectrum of activity scale.
Calculation of spectrum scores for combination
antimicrobial therapy
To account for overlapping coverage in combination
regimens, the following approach was taken. First, if
none of the regimen antimicrobials possessed activity
against a species, a zero was assigned to the organism-
combination regimen pair. If one of the regimen antimi-
crobials possessed activity against a species, the active
antimicrobial susceptibility was used to populate the
organism combination regimen pair. For other regimens
where a combination of antimicrobials possessed activity
against a species, the proportion of organisms suscep-
tible to a multi-antimicrobial regimen was estimated as
one minus the joint probability of resistance to all regi-
men antimicrobials, assuming that antibiotic susceptibil-
ities were independent [7]. Spectrum scores were then
computed identically to individual antimicrobial regi-
mens. Table 1 illustrates the steps involved in generating
spectrum score values for an individual and combination
antimicrobial regimens.
Application of the spectrum score method to measure
de-escalation
Inpatient antimicrobial administration within the VA is
documented utilizing Bar Code Medication Administra-
tion (BCMA) technology. For each administered dose of
antimicrobial, data regarding the dose and route of ad-
ministration are recorded electronically with a time
stamp [43]. Antimicrobial use data was obtained for a
VA-wide cohort (years 2008–2012) of inpatient admis-
sions with HCAP [8,44]. Each systemically administered
antimicrobial the patient received during each calendar
day of admission was extracted from the CDW [45]. Ascombination antimicrobial therapy was commonly ad-
ministered, data were “smoothed” to prevent over and
under-calculation of spectrum scores on days when dif-
ferent antimicrobials were simultaneously being initiated
or discontinued. Smoothing was accomplished by infer-
ring the intent to treat from antimicrobial administration
data. Skip days, where antibiotics that were administered
less frequently than once daily, were filled when between
adjacent calendar days where the same antibiotic was ad-
ministered (e.g., vancomycin administered every 48 hours).
Skip days were assigned the same antibiotic regimen as
the adjacent calendar days. To avoid double counting anti-
biotics when an antibiotic regimen was switched, an anti-
biotic day was not counted when there was a change in a
multidrug regimen from the current, previous, and next
days, the antibiotic was given in the past two days but not
in the next three, and the day did not fall on the beginning
or end of an antibiotic treatment course. For example,
switching from cefepime and vancomycin to levofloxacin
and clindamycin on day 4 would appear as a four-drug
regimen unless these rules are invoked, in which case only
the latter regimen would be counted (Table 2).
Spectrum score method refinement and validation
Refinement and validation of the spectrum score method
was performed in three stages. First, 300 vignettes were
created based on daily antimicrobial regimens obtained
from a random sample of patients who met HCAP criteria
[8,44]. Vignettes included antimicrobials administered on
each calendar day of hospitalization and microbiology
findings obtained in the first two days. Three antimicro-
bial stewards [mean (SD) 17.3 (0.7) years of experience]
who were unfamiliar with the spectrum score method
reviewed the vignettes. The stewards ranked each case on
a 7-point Likert scale: de-escalation (score >4), no mean-
ingful change in therapy (score =4), or escalation (score
of < 4). Spectrum scores were determined for regimens
administered on calendar days 2 and 4 of hospitalization;
day 4 scores were subtracted from day 2 scores resulting
in a spectrum score Δ for each vignette. A positive
spectrum score Δ indicated de-escalation. Sensitivity and
specificity of the sign of spectrum score Δ to predict anti-
microbial steward de-escalation opinion (i.e., reference
standard) were calculated. To determine if varying the
weight for coverage of resistant organisms impacted test
characteristics of the method, spectrum score variants with
differing weights (no weight, 1.25, 1.5, 1.75, 2.0, 3.0) for
coverage of these organisms were calculated for the cases,
and then compared to expert opinion in a similar manner.
Based upon observations in the initial exercise, 40 pairs
of vignettes were modified to include the administration
route for each antimicrobial. Each pair of vignettes con-
tained identical or almost identical antimicrobial regimens
with the same spectrum; however, in one case the regimen
Table 1 Conceptual illustration of spectrum score calculation for an antimicrobial regimen

















Staphylococcus aureus 99.3 4 51.2 2 99.6 4
Streptococcus pneumoniae 98.2 4 92.5 4 99.9 4
Enterococcus faecium 18.4 0 NA 0 18.4 0
Enterococcus faecalis 94.7 4 NA 0 94.7 4
Escherichia coli NA 0 92.4 4 92.4 4
Klebsiella spp. NA 0 84.5 4 84.5 4
Other enterobacteriaceaeC NA 0 91.3 4 91.3 4
Pseudomonas aeruginosa NA 0 78.0 3 78.0 3
Acinetobacter spp. NA 0 42.6 2 42.6 2
Stenotrophomonas spp. NA 0 36.6 1 36.6 1
Haemophilus influenzae NA 0 95.4 4 95.4 4
Bacteroides spp. NA 0 NA 0 NA 0
Legionella spp. NA 0 NA 0 NA 0
Mycoplasma spp. NA 0 NA 0 NA 0







Vancomycin + cefepime weighted
ordinal score
Staphylococcus aureus 5 2.5 5
Streptococcus pneumoniae 4 4 4
Enterococcus faecium 0 0 0
Enterococcus faecalis 4 0 4
Escherichia coli 0 5 5
Klebsiella spp. 0 5 5
Other enterobacteriaceaeC 0 4 4
Pseudomonas aeruginosa 0 5.25 5.25
Acinetobacter spp. 0 2.5 2.5
Stenotrophomonas spp. 0 1 1
Haemophilus influenzae 0 4 4
Bacteroides spp. 0 0 0
Legionella spp. 0 0 0
Mycoplasma spp. 0 0 0
Spectrum Score 13.0 33.25 39.75
Spectrum Score Calculations for Individual and Combination Antibiotic Regimens. AValues populated with susceptibility data. Susceptibility estimates for
combinations where all antimicrobials possessed activity against the species obtained by calculating one minus the joint probability of resistance to all antibiotics
in the regimen, assuming that susceptibility was independent for each antibiotic. BOther enterobacteriaceae included: Citrobacter spp., Enterobacter spp.,
Morganella spp., Proteus spp., Providencia spp., Serratia spp. CNA = No intrinsic activity. DOrdinal values were 0 for no intrinsic bacterial activity or susceptibility < 20%,
1 for > 20 but < 40%, 2 for >40 but < 60%, 3 for >60 but < 80%, 4 > 80 %. EA weight of 1.25 was applied to ordinal domain values for Staphylococcus aureus,
Escherichia coli, Klebsiella spp., Acinetobacter spp., Enterococcus faecium, and a weight of 1.75 was applied to spectrum score values for Pseudomonas aeruginosa.
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tered orally (PO) whereas in the other case all antimicro-
bials were administered intravenously (IV) (i.e. amoxicillin
versus ampicillin). These cases were evaluated by the same
experts and compared to the spectrum score Δ asdescribed. Mean paired difference in Likert scores be-
tween the IV and PO cases was calculated for pairs in
which the PO case had 50-100% PO therapy and for pairs
with >0% but less than 50% PO therapy on day 4. A linear
regression model relating mean Likert and spectrum score
Table 2 Example of a prediction of antimicrobial de-escalation status by the spectrum score method
A. Daily antimicrobial (Route of administration) use data
Antimicrobial/Day Hospital day 1 Hospital day 2 Hospital day 3 Hospital day 4 Hospital day 5
Clindamycin (Clm) Clm (PO) Clm (PO)
Levofloxacin (Lev) Lev (PO) Lev (PO)
Cefepime (Cpm) Cpm(IV) Cpm(IV) Cpm (IV) Cpm (IV)
Vancomycin (Vm) Vm (IV) Vm (IV) Vm (IV) Vm (IV)
Daily Regimen Spectrum Score 39.75 39.75 39.75 55.00 44.25
B. Application of “smoothing” rules to daily antimicrobial use data
Antimicrobial/Day Hospital day 1 Hospital day 2 Hospital day 3 Hospital day 4 Hospital day 5
Clindamycin (Clm) Clm (PO) Clm (PO)
Levofloxacin (Lev) Lev (PO) Lev (PO)
Cefepime (Cpm) Cpm(IV) Cpm (IV) Cpm (IV)
Vancomycin (Vm) Vm (IV) Vm (IV) Vm (IV)
Daily Regimen Spectrum Score 39.75 39.75 39.75 44.25 44.25
C. Calculation of spectrum score Δ (Day 2 spectrum score – Day 4 spectrum score)
[Cefepime + vancomycin score] – [Clindamycin + levofloxacin score] = Spectrum score Δ
39.75 – 44.25 = -4.5
D. Adjustment of spectrum score Δ for PO antimicrobials administered on day 4
Spectrum score Δ + Administration credit Final spectrum score Δ after PO adjustment
-4.5 + 6 1.5
A. Example of antimicrobials administered on a daily basis during a 5 day hospitalization. Days 2 and 4 indicate baseline and de-escalation determination endpoints.
Note that the daily antimicrobial regimen spectrum score increases on day 4 due to the addition of oral antimicrobials; however, IV antimicrobials are discontinued.
B. Smoothing rules were applied to the daily antimicrobial administration data which results in a lower day 4 spectrum score. C. The spectrum score Δ is negative
suggesting that the spectrum of activity of is greater for the clindamycin + levofloxacin regimen than for the cefepime + vancomycin combination. D. The PO credit is
applied to the case because 100% of the antimicrobials on day 4 were administered PO (6 points for regimens with ≥ 50 % of antimicrobials administered PO by day 4).
The final spectrum score Δ with PO credit is positive prediciting that a de-escalation event occurred.
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was used to express the means of paired difference in
Likert in spectrum score scale (paired Likert means di-
vided by the slope). The mean values converted to the
spectrum score scale provided additional credits to the
spectrum score Δ to account for vignettes with minimal
conversion to PO therapy (>0% but <50%) and greater or
full conversion to PO therapy (50%-100%) on day 4. Fi-
nally, 100 vignettes were selected from the original 300
HCAP cases and the route of antimicrobial administration
data was added. These vignettes were assessed for de-
escalation status by three new antimicrobial stewards un-
familiar with the spectrum score method [mean (SD) 14.0
(5.2) years of experience] using the same 7-point Likert
scale. Mean Likert scores were compared to the spectrum
score Δ credited for IV to PO conversion. Only vignettes
with 100% IV therapy on day 2 were eligible for the credit.
Test characteristics of the spectrum score method to pre-
dict antimicrobial de-escalation were performed as above.
Table 2 illustrates application of the spectrum score
method to measure de-escalation in a theoretical case, and
Figure 1 summarizes the process for development, refine-
ment, and validation of the spectrum score method. A
procedure that can be used to apply the spectrum score
method is available in Additional files 1 and 2.This research complies with all Federal guidelines and
VA policies relative to Human Subjects and research.
The VA Puget Sound Healthcare System, University of
Utah, and Idaho State University Human Subjects Com-
mittees approved the study and its conduct was in com-
pliance with the Helsinki Declaration.
Results
Spectrum score calculations
Spectrum scores were determined for 14 organism do-
mains which included 19 bacterial species and 27 cat-
egories of antimicrobials. Table 3 illustrates the ordinal
susceptibility scores for organism-antimicrobial pairs.
There were 513 possible organism-antimicrobial pairs
for consideration of which 53% had sufficient VA sus-
ceptibility data, 6% were determined by applying CLSI-
based rules, 28% were identified as possessing NA, and
15% required further confirmation or determination of
susceptibility results with external sources. Suitable
references could not be identified in a 3% of cases and
domain scores were assigned by investigator opinion.
Spectrum score method refinement and validation
Findings for the initial validation exercise have recently
been overviewed [7]. Briefly, there were 142 distinct
Figure 1 Overview of the process for development, refinement, and
validation of the spectrum score method.
Madaras-Kelly et al. BMC Infectious Diseases  (2015) 15:197 Page 6 of 12antimicrobial regimens (79% combination regimens) ad-
ministered in the 300 HCAP patient cases. Day 2 and 4
spectrum scores in the vignettes ranged from a mini-
mum of 4.0 to a maximum of 60.0. The sensitivity and
specificity of the spectrum score method to identify anti-
microbial de-escalation events as determined by anti-
microbial stewards was 86.3 and 96.0%, respectively.
Adjustment of weights assigned for coverage of intrinsic-
ally resistant organisms did not improve the sensitivity
and specificity of the spectrum score method beyond the
weighting proposed by the Delphi panel, and spectrum
score Δ was more predictive of de-escalation events with
application of these weights (P = 0.05, difference in area
under the curve between weighted and un-weighted
receiver operator curves). Upon inspection, it appeared
that in select vignettes stewards inferred that a patient
received a PO antimicrobial on day 4 even though theroute of antimicrobial administration was not stated (e.g.,
ceftriaxone administered on day 2 followed by cefpodox-
ime administered on day 4). Despite many of these regi-
mens possessing similar spectrum scores (i.e., spectrum
score for both ceftriaxone or cefpodoxime was 25.25) , ex-
perts scored these vignettes higher if regimens contained
antimicrobials with PO dosage forms available compared
to regimens with IV antibiotics on day 4 (e.g., ceftriaxone
on day 2 and day 4).
In the second vignette exercise, the mean (± SD)
Likert score for paired vignettes containing identical or
nearly identical antimicrobials with the same spectrum
but differing routes of administration by day 4 was 5.0
(1.5) and 4.6 (1.5) for PO and IV cases (P = 0.002),
respectively. The mean (± SD) paired difference in Likert
scores was 0.44 (0.50) for pairs where the percentage of
PO therapy in the PO case was 50-100% by day 4 (P <
0.001) and 0.24 (0.68) for pairs where the percentage of
PO therapy was > 0% but < 50% in the PO case by day 4
(P = 0.12). Based on the linear relationship between
mean Likert score and weighted spectrum score Δ
(slope = 0.072, P < 0.001) for vignettes with 100% IV
therapy on day 2 and day 4, the paired mean difference
in Likert score for vignettes with 50-100% PO therapy
on day 4 was equivalent to approximately 6 spectrum
score points, and was equivalent to approximately 3
spectrum score points for >0% but <50% PO therapy on
day 4. Adding the two credits to spectrum score Δs for
applicable regimens improved detection of de-escalation
events in the set of paired vignettes as classified by stew-
ardship experts.
In the final exercise, the sensitivity and specificity of
the spectrum score method, including the credit for PO
antimicrobials to predict de-escalation events was 96.2
(95% CI >88.6%) and 93.6% (95% CI >84.3%), respect-
ively. Antimicrobial stewards identified de-escalation, no
meaningful change in therapy, or escalation in 53, 41,
and 6% of vignettes reviewed whereas, the spectrum
score method with credits identified de-escalation, no
meaningful change in therapy, or escalation by day 4 of
therapy in 54, 42, and 4 of these vignettes, respectively.
Agreement between reviewers was high [Mean (±95%
CI) intra-class correlation coefficient 0.86 (0.81-0.91)].
The sensitivity of the spectrum score method without
PO credits to predict steward judgments of de-escalation
events was only 56.7% (specificity 97.9%). Vignettes
included in the final exercise were created as a subset of
the initial 300 cases, and comparison of the mean (±SD)
Likert scores for vignettes included in both the initial
and final and exercises was 4.2(1.3) and 4.6 (1.1), re-
spectively (P <0.003).
Taken together the vignette exercises suggest that in-
clusion of the route of administration was an important
consideration in the assessment of de-escalation events,
Table 3 Ordinal susceptibility scores for antimicrobial-organism pairs included in the spectrum score
Anti-MRSA* βL- Inhibitors** Carbapenems & aztreonam*** Cephalosporins****
Vanc Lzld Tig Dapto Ceftar Pip/Taz Tic/Clav Amino-BLI PSA
Carb









Staphylococcus aureus 4Ϯ 4Ϯ 4Ϯ 4Ϯ 4κ 2¥ 2¥ 2¥ 2¥ 2¥ 0I 2¥ 2¥ 2¥ 2¥
Streptococcus pneumoniae 4Ϯ 4Ϯ 4κ 0Ψ 4κ 3¥ 3¥ 3¥ 4Ϯ 4Ϯ 0I 3Ϯ 3Ϯ 4Ϯ 4Ϯ
Enterococcus faecalis 4Ϯ 4Ϯ 4Ϯ 4Ϯ 0¥ 4Ϯ 4κ 4Ϯ 4Ϯ 0κ 0I 0¥ 0¥ 0¥ 0¥
Enterococcus faecium 4Ϯ 4Ϯ 4Ϯ 4Ϯ 0¥ 1Ϯ 1κ 1Ϯ 0Ϯ 0κ 0I 0¥ 0¥ 0¥ 0¥
Gram negative organisms
Escherichia coli 0I 0I 4Ϯ 0I 4κ 4Ϯ 4Ϯ 3Ϯ 4Ϯ 4Ϯ 4Ϯ 4Ϯ 4Ϯ 4Ϯ 4Ϯ
Klebsiella spp. 0I 0I 4Ϯ 0I 4κ 4Ϯ 4Ϯ 4Ϯ 4Ϯ 4Ϯ 4Ϯ 4Ϯ 4Ϯ 4Ϯ 4Ϯ
OtherEnterobacteriaceae 0I 0I 3Ϯ 0I 3κ 4Ϯ 4Ϯ 2Ϯ 4Ϯ 4Ϯ 4Ϯ 1Ϯ 2Ϯ 4Ϯ 4Ϯ
Enterobacter spp. 0I 0I 4Ϯ 0I 3κ 4Ϯ 3Ϯ 0Ϯ 4Ϯ 4Ϯ 4Ϯ 0Ϯ 1Ϯ 4Ϯ 4Ϯ
Citrobacter spp. 0I 0I 4Ϯ 0I 4κ 4Ϯ 4Ϯ 3Ϯ 4Ϯ 4Ϯ 4Ϯ 2Ϯ 3Ϯ 4Ϯ 4Ϯ
Serratia spp. 0I 0I 4Ϯ 0I 3κ 4Ϯ 4Ϯ 0Ϯ 4Ϯ 4Ϯ 4Ϯ 0Ϯ 0Ϯ 4Ϯ 4Ϯ
Morganella spp. 0I 0I 2Ϯ 0I 3κ 4Ϯ 3Ϯ 0Ϯ 4Ϯ 4Ϯ 4Ϯ 0Ϯ 0Ϯ 4Ϯ 4Ϯ
Proteus spp. 0I 0I 1Ϯ 0I 4κ 4Ϯ 4Ϯ 4Ϯ 4Ϯ 4Ϯ 4Ϯ 4Ϯ 4Ϯ 4Ϯ 4Ϯ
Providencia spp. 0I 0I 2Ϯ 0I 0Ψ 4Ϯ 4Ϯ 0 4Ϯ 4Ϯ 4Ϯ 0Ϯ 2Ϯ 4Ϯ 4Ϯ
Pseudomonas aeruginosa 0I 0I 0I 0I 0I 4Ϯ 4Ϯ 0I 4Ϯ 1Ϯ 4Ϯ 0I 0I 0Ϯ 4Ϯ
Acinetobacter spp. 0I 0I 4Ϯ 0I 0κ 3Ϯ 3Ϯ 3Ϯ 3Ϯ 0κ 0Ϯ 0Ψ 0Ψ 1Ϯ 3Ϯ
Stenotrophomonas spp. 0I 0I 3Ϯ 0I 0κ 3Ϯ 2Ϯ 0I 0Ϯ 0κ 0Ϯ 0Ψ 0Ψ 0Ϯ 1Ϯ
Haemophilus influenzae 0I 0κ 4κ 0I 4κ 4¥ 4Ψ 4Ϯ 4Ϯ 4κ 4κ 3Ψ 4Ϯ 4Ϯ 4Ϯ
Bacteroides spp. 0I 0κ 4κ 0I 0I 4Ϯ 3Ω 4Ϯ 4Ϯ 4¥ 0I 0I 0I 1Ϯ 0I
Other organisms
Atypical organisms 0I 0κ 4κ 0I 0I 0I 0I 0I 0I 0I 0I 0I 0I 0I 0I
Legionella spp. 0I 0κ 4κ 0I 0I 0I 0I 0I 0I 0I 0I 0I 0I 0I 0I
Mycoplasma spp. 0I 0κ 4κ 0I 0I 0I 0I 0I 0I 0I 0I 0I 0I 0I 0I
Penicillins***** Miscellaneous******
Amino PCN Semi Synth
PCN
PSAFQ NON-PSAFQ Amik Gent or
Tobra
Macro Clinda Tetra TMP/SMX Metro Colistin
Gram positive organisms
Staphylococcus aureus 0Ϯ 2Ϯ 2Ϯ 3Ϯ 4Ϯ 4Ϯ 1Ϯ 3Ϯ 4Ϯ 4Ϯ 0I 0κ
Streptococcus pneumoniae 3Ϯ 3¥ 4Ϯ 4Ϯ 0κ 0κ 3Ϯ 4Ϯ 3Ϯ 3Ϯ 0I 0κ
Enterococcus faecalis 4Ϯ 0κ 3Ϯ 3Ϯ 0I 0I 0Ϯ 0¥ 1Ϯ 0¥ 0I 0κ














Table 3 Ordinal susceptibility scores for antimicrobial-organism pairs included in the spectrum score (Continued)
Gram negative organisms
Escherichia coli 2Ϯ 0I 3Ϯ 3Ϯ 4Ϯ 4Ϯ 0I 0I 3Ϯ 3Ϯ 0I 4Ϯ
Klebsiella spp. 0Ϯ 0I 4Ϯ 4Ϯ 4Ϯ 4Ϯ 0I 0I 4Ϯ 4Ϯ 0I 4Ϯ
OtherEnterobacteriaceae 1Ϯ 0I 3Ϯ 3Ϯ 4Ϯ 4Ϯ 0I 0I 2Ϯ 4Ϯ 0I 2Ϯ
Enterobacter spp. 0Ϯ 0I 4Ϯ 4Ϯ 4Ϯ 4Ϯ 0I 0I 4Ϯ 4Ϯ 0I 4Ϯ
Citrobacter spp. 0Ϯ 0I 4Ϯ 4Ϯ 4Ϯ 4Ϯ 0I 0I 4Ϯ 4Ϯ 0I 4Ϯ
Serratia spp. 0Ϯ 0I 4Ϯ 4Ϯ 4Ϯ 4Ϯ 0I 0I 0Ϯ 4Ϯ 0I 3Ϯ
Morganella spp. 0Ϯ 0I 3Ϯ 2Ϯ 4Ϯ 4Ϯ 0I 0I 1Ϯ 3Ϯ 0I 1Ϯ
Proteus spp. 3Ϯ 0I 3Ϯ 3Ϯ 4Ϯ 4Ϯ 0I 0I 0Ϯ 3Ϯ 0I 0κ
Providencia spp. 0Ϯ 0I 2Ϯ 2Ϯ 4Ϯ 2Ϯ 0I 0I 0Ϯ 3Ϯ 0I 0Ψ
Pseudomonas aeruginosa 0I 0I 3Ϯ 1Ϯ 4Ϯ 4Ϯ 0I 0I 0I 0I 0I 4Ϯ
Acinetobacter spp. 0Ϯ 0I 3Ϯ 2Ϯ 4Ϯ 3Ϯ 0I 0I 2Ϯ 3Ϯ 0I 4Ϯ
Stenotrophomonas spp. 0Ϯ 0I 4Ϯ 2Ϯ 2Ϯ 1Ϯ 0I 0I 3Ϯ 4Ϯ 0I 4Ϯ
Haemophilus influenzae 3¥ 0I 4Ϯ 4Ϯ 4κ 4κ 4Ϯ 0Ψ 4Ϯ 3Ϯ 0I 4κ
Bacteroides spp. 0Ϯ 0I 2κ 2¥ 0I 0I 0κ 3Ϯ 1κ 0κ 4Ϯ 0I
Other organisms
Atypical organisms 0I 0I 4κ 4κ 2κ 2κ 4κ 0κ 4κ 2κ 0I 0I
Legionella spp. 0I 0I 4κ 4κ 4κ 0κ 4κ 0κ 4κ 4κ 0I 0I
Mycoplasma spp. 0I 0I 4κ 4κ 0Ψ 0Ψ 4κ 0κ 4κ 0κ 0I 0I
Special Notations:
Ϯ VA susceptibility data.
I No intrinsic activity.
Ψ Investigator opinion.




*Anti-MRSA: Vanc = vancomycin; Lzld = linezolid; Tig = tigecycline; Dapto = daptomycin, Ceftar = ceftaroline.
**βL- Inhibitors: Pip/Taz = piperacillin/tazobactam; Tic/Clav = ticarcillin/clavulanate; AminoBLI = ampicillin/sulbactam, amoxicillin/clavulanate.
***Carbapenems and Aztreonam: PSACarba = imipenem, meropenem, Erta = ertapenem, Aztr = aztreonam.
****Cephalosporins: 1st Gen Ceph. = cefazolin, cephalexin; 2nd Gen Ceph = cefuroxime; 3rd Gen Ceph = ceftriaxone, cefotaxime, cefpodoxime; PSACeph = cefepime, ceftazidime.
*****Penicllins: AminoPCN = ampicillin, amoxicillin, penicillin; SemiSynthPCN = oxacillin, nafcillin.
******Miscellaneous: PSAFQ = ciprofloxacin or levofloxacin; NONPSAFQ =moxifloxacin, gemifloxacin; Amik = Amikacin; Gent or Tobra = gentamicin, tobramycin; Macro = erythromycin, azithromycin, clarithromycin;














Madaras-Kelly et al. BMC Infectious Diseases  (2015) 15:197 Page 9 of 12and that IV to PO conversion was viewed favorably
when assessing de-escalation events. Table 4 summarizes
the three refinement and validation exercise findings.
There were five discordant cases between the spec-
trum score with PO credits and reference method. Tet-
racyclines, which were only included in five vignettes,
were involved in three of the discordant cases. Reviewers
scored regimens in favor of de-escalation when tetracy-
clines were included on day 4 compared to the spectrum
score method. Another discordant case involved the
addition of a duplicative spectrum PO antibiotic to an IV
regimen on day 4, which was classified an escalation by re-
viewers and a de-escalation by the spectrum score method
due to the PO credit awarded. In the final discordant case,
one of four antimicrobials was administered PO on day 2,
but the antimicrobials remained identical on day 4 with
two antimicrobials administered by the PO route. Experts
scored this case as a de-escalation; however the case was
not eligible for the credit as not all antimicrobials were
administered IV on day 2.
Discussion
The spectrum score method and findings are unique,
and we are unaware of studies where definitions of anti-
microbial de-escalation have been compared. Develop-
ment of this approach was based in part on the opinions
of antimicrobial stewards obtained during the Delphi
process which enhanced construct validity. In the ab-
sence of a clear reference standard we compared the
spectrum score method to that of antimicrobial stewards
who have the most expertise and interest in the meas-
urement of de-escalation events. A major finding of this
investigation includes the high degree of agreement
between the spectrum score predictions of de-escalation











Convergent validation of original
spectrum score
86.3 96.0 87.5 95.
Refinement exercise to verify
that IV to PO conversion
impacted expert opinion of
de-escalation events




96.2 93.6 94.4 95.patient-level which suggests convergent validity. A sec-
ond major finding is the observation that antimicrobial
stewards view IV to PO conversion favorably when clas-
sifying de-escalation events. Frequently clinicians make
pragmatic tradeoffs when altering antimicrobial therapy
in preparation for discharge which sometimes may be
viewed as therapy simplification rather than verbatim
selection of the most narrow-spectrum antimicrobial.
While addition of the PO credits improved the sensitiv-
ity to detect de-escalation events classified by stewards,
providing information on the route of antimicrobial
administration to the experts in addition to the specific
antimicrobials administered resulted in an increase in
classification of de-escalation events in the vignettes.
Further, the sensitivity to detect de-escalation events
based on spectrum alone decreased when the route of
administration information was added to the cases. The
observation that stewards perceived tetracyclines as a
relatively narrow-spectrum antimicrobial class despite
susceptibility data to the contrary is also interesting. The
reason behind this perception is unclear but may be
related to the use of tetracyclines almost exclusively for
coverage of atypical pathogens in treatment of pneumo-
nia within the U.S., or a (subconscious) tendency to con-
sider use of older drugs as a form of de-escalation.
Strengths of the method are that it was developed
based upon the opinions of antimicrobial stewards and
is anchored within the constructs of objective VA-wide
microbial susceptibility data. The decision points of hos-
pital day 2 and day 4 to measure baseline and follow-up
therapy were supported as favorable time-points for
measuring de-escalation events by antimicrobial stew-
ards [7,46]. An additional strength of the method is that
it can be adapted to classify antimicrobial de-escalation





6 Reference standard de-escalation prevalence in vignettes
was 24.2%. Route of administration data not included in
cases. Mean Likert score was 0.51 points higher for cases
where regimens contained≥ 1 antimicrobial available in a
PO dosage form administered on day 4 (p = 0.003).
Mean Likert scores for regimens containing similar
antimicrobials but differing routes of administration by
day 4 was 5.0 (1.5) and 4.6 (1.5) for PO and IV cases
(P = 0.002), respectively. Linear regression used to estimate
an additional credit to the spectrum score Δ to account for
the group mean differences in Likert score associated with
conversion from IV to PO therapy. A 6 point credit was
added to spectrum score Δ values for regimens with >50-100%
PO and 3 point credit for regimens >0 but < 50% PO.
7 Reference standard de-escalation prevalence in vignettes was
53.0%. Route of administration data included in cases and PO
credits applied to spectrum score Δ.
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microbiology data to define spectrum score values. Anti-
microbial susceptibilities and hence spectrum scores will
likely change over time; which will require a regular re-
evaluation of organism-antimicrobial susceptibilities. Fur-
ther, in some instances VA susceptibility data were lacking
and published susceptibility estimates were dated. It is
possible that differences in susceptibility patterns across
facilities may impact drug selection and de-escalation
practice; however in an attempt to minimize these differ-
ences, we converted susceptibility estimates to ordinal
values to facilitate generalization and organisms with
MDR potential were weighted more heavily in accordance
with Delphi panel preferences. The number of antimicro-
bial stewardship experts rendering judgments on de-
escalation events was limited, and consensus was not
obtained on all patient cases. In the final validation exer-
cise, sensitivity of the method to detect de-escalation events
in the vignettes was highly dependent on the addition of
PO credits. It is important to remember that the estimates
for de-escalation were generated from vignettes which were
based upon antimicrobial regimens administered to pa-
tients in the cohort. In limited cases it was necessary to
makes slight modifications of regimens to fit the vignette
format, and it is unknown if the observed de-escalation rate
reflects the actual de-escalation rate as measured in pa-
tients. However, the importance of PO conversion was
identified in all three validation and refinement exercises.
Conversely, disagreements between the spectrum score
method and the expert judgments are to be expected, and
lack of 100% agreement is not evidence for lack of validity.
Antimicrobial de-escalation and IV to PO conversion
programs have been associated with reductions in length
of hospitalization, inpatient antimicrobial use, adverse
events, cost, and recovery of antimicrobial-resistant mi-
crobes [1,5,47-49]. However, few studies have clearly de-
fined how de-escalation status was measured, and the
quality of evidence in this area is poor [5,50]. The use of
a limited scoring system based upon Gram-negative ac-
tivity of anti-pseudomonal β-lactam and fluoroquinolone
antibiotics has been previously described [51]. Recently,
quality indicators for the management of antimicrobial
use in sepsis have been described that recommend
“changing to pathogen-directed therapy after culture-
results become available” [52]. An IV to PO conversion
quality measure has also been proposed for highly bio-
available antimicrobials in a clinically stable population;
however we are unaware of recommendations that in-
corporate both concepts into a single measure [53].
Future work should include application and automa-
tion of the spectrum score method to measure anti-
microbial de-escalation in electronic medical records.
We are currently conducting such an analysis of VA-wide
facility-level de-escalation rates in HCAP. Additional workshould also include an assessment of the importance of
PO therapy in the assessment of de-escalation therapy.
Further, validation of the spectrum score method to esti-
mate antimicrobial de-escalation in other patient popu-
lations, disease states, and electronic medical records
systems is warranted.
Conclusions
The spectrum score method exhibited excellent agree-
ment with antimicrobial steward judgments of antimicro-
bial de-escalation events in pneumonia. The method,
which is based upon the spectrum of antimicrobial regi-
mens administered at subsequent time-points during
hospitalization and the utilization of IV to PO conversion,
can be applied to electronic medical records data to assess
antimicrobial de-escalation in patients with healthcare
associated pneumonia.
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